PS
CDTX

Principal Securities’s Cidara Therapeutics CDTX Stock Holding History

Principal Securities’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12
Closed -$1.15K – 1683
2025
Q3 		$1.15K Buy
+12
New +$766 ﹤0.01% 3377

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Principal Securities's CDTX Position: Q4 2025 in Review

Principal Securities sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 12 shares — an estimated $1.15K sold.

Principal Securities first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $1.15K in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Principal Securities reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 12 Cidara Therapeutics shares in Q4 2025, an estimated $1.15K.
  • Principal Securities first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
  • Principal Securities's Cidara Therapeutics position peaked at $1.15K in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.